No headlines found.
PRNewswire (Wed, 18-Dec 7:35 AM ET)
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
PRNewswire (Tue, 26-Nov 4:03 PM ET)
Accuray Reports Fiscal 2025 First Quarter Financial Results
PRNewswire (Wed, 6-Nov 4:05 PM ET)
Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024
PRNewswire (Wed, 23-Oct 4:05 PM ET)
Accuray Appoints Michael Murphy as VP, Corporate Controller
PRNewswire (Mon, 21-Oct 4:05 PM ET)
PRNewswire (Thu, 17-Oct 7:00 AM ET)
Accuray President and Chief Executive Officer Suzanne Winter Returns from Medical Leave of Absence
PRNewswire (Tue, 15-Oct 8:45 AM ET)
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Accuray trades on the NASDAQ stock market under the symbol ARAY.
As of January 2, 2025, ARAY stock price declined to $1.95 with 485,119 million shares trading.
ARAY has a beta of 3.28, meaning it tends to be more sensitive to market movements. ARAY has a correlation of 0.23 to the broad based SPY ETF.
ARAY has a market cap of $196.10 million. This is considered a Micro Cap stock.
Last quarter Accuray reported $102 million in Revenue and -$.04 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.01.
In the last 3 years, ARAY traded as high as $4.87 and as low as $1.40.
The top ETF exchange traded funds that ARAY belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
ARAY has underperformed the market in the last year with a return of -31.1%, while SPY returned +24.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ARAY shares. However, ARAY has outperformed the market in the last 3 month and 2 week periods, returning +8.3% and +2.1%, while SPY returned +2.2% and -2.9%, respectively. This indicates ARAY has been having a stronger performance recently.
ARAY support price is $1.90 and resistance is $2.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARAY shares will trade within this expected range on the day.